Pharmacologic Treatment of Posttraumatic Stress Disorder: A Focus on Antipsychotic Use

References

• Solomon S, Davidson JRT: Trauma: Prevalence, impairment, service use, and cost. J Clin Psychiatry 1997; 58(9):5–11
   PubMed Web of Science ®Google Scholar
• Hidalgo RD, Davidson JRT: Posttraumatic stress disorder: Epidemiology and health-related considerations. J Clin Psy-chiatry 2000; 61(7):5–13
   Google Scholar
• Kessler RC: Posttraumatic stress disorder: The burden to the individual and to society. J Clin Psychiatry 2000; 61(5):4–14
   PubMed Web of Science ®Google Scholar
• Ferrada-Noli M, Asberg M, Ormstad K, Lundin T, Sundbom E: Suicidal behavior after severe trauma, Pt 1: PTSD diagnoses, psychiatric comorbidity, and assessments of suicidal behavior. J Trauma Stress 1998; 11:103–112
   PubMed Web of Science ®Google Scholar
• Breslau N, Davis GC, Andreski P. Peterson E: Traumatic events and posttraumatic stress disorder in an urban popu-lation of young adults. Arch Gen Psychiatry 1991; 48:216–222
   Google Scholar
• Breslau N, Kessler RC, Chilcoat HD, Schultz LR, Davis GC, Andreski P: Trauma and posttraumatic stress disorder in the community. The 1996 Detroit area survey of trauma. Arch Gen Psychiatry 1998; 55:626–632
   Google Scholar
• Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB: Posttraumatic stress disorder in the National Comorbidity Sur-vey. Arch Gen Psychiatry 1995; 52:1048–1060
   PubMed Web of Science ®Google Scholar
• Breslau N: The epidemiology of posttraumatic stress disorder:What is the extent of the problem? J Clin Psychiatry 2001: 62(17):16–22
   PubMed Web of Science ®Google Scholar
• Davidson JR, Hughes D, Blazer DG, George LK: Posttrau-matic stress disorder in the community: An epidemiological study. Psychol Med 1991; 21:713–721
   PubMed Web of Science ®Google Scholar
• Breslau N, Chilcoat HD, Kessler RC, Davis GC: Previous ex-posure to trauma and PTSD effects of subsequent trauma: Results from the Detroit Area Survey of Trauma. Am J Psy-chiatry 1999; 56:902–907
   Google Scholar
• Bromet E, Sonnega A, Kessler RC: Risk factors for DSMIIIR PTSD: Findings from the National Comorbidity Survey. Am J Epidemiol 1998; 147:343–361
   Google Scholar
• Center for Disease Control. Vietnam Experience Study: Psy-chological and Neuropsychological Evaluation. Atlanta, GA: Center for Disease Control; 1988
   Google Scholar
• Davidson JRT: Pharmacotherapy of posttraumatic stress dis-order: Treatment options, long-term follow-up, and pre-dictors of outcome. J Clin Psychiatry 2000; 61(5):52–56
   Google Scholar
• Hageman I, Andersen HS, Jorgensen MB: Posttraumatic stress disorder: A review of psychobiology and pharmacotherapy. Acta Psychiatr Scand 2001; 104:411–422
   PubMed Web of Science ®Google Scholar
• Cyr M, Farrar K: Treatment of posttraumatic stress disorder. Ann Pharmacother 2000; 34:366–376
   PubMedGoogle Scholar
• Stein DJ, Zungu-Dirwayi N, van der Linden GJH, Seedat S: Pharmacotherapy of posttraumatic stress disorder. Cochrane Lib 2002; 2:1–37
   Google Scholar
• 'nicker P, Trautman R: Understanding and treating PTSD: Past, present, and future. Bull Meninger Clin 2000; 64(3, Suppl A):37–51
   Google Scholar
• Connor KM, Davidson JRT: Pharmacotherapy for posttrau-matic stress disorder: Beyond the SSRls. Intl. Drug Ther 2002; 37(6):41–48
   Google Scholar
• Ballenger JC, Davidson JRT, Lecrubier Y, Nutt DJ, Foa EB, Kessler RC, McFarlane AC, Shalev AY: Consensus statement on posttraumatic stress disorder from the international con-sensus group on depression and anxiety. J Clin Psychiatry 2000; 61(5):60–66
   PubMed Web of Science ®Google Scholar
• Post RM, Weiss SRB, Smith M, Li H, McCann U: Kindling versus quenching: Implications for the evolution and treat-ment of in posttraumatic stress disorder. Ann NY Acad Sci 1997; 821:285–295
   Web of Science ®Google Scholar
• Wolfe ME, Alavi A, Mosnaim AD: Posttraumatic stress disor-der in Vietnam veterans: Clinical and EEG findings; possible therapeutic effects of carbamazepine. Biol Psychiatry 1988; 23:642–644
   Google Scholar
• Lipper S, Davidson JRT, Grady TA, Edinger JD, Hammett EB, Mahorney SL, Cavenar JO, Jr.: Prelimi-nary study of carbamazepine in posttraumatic stress disorder. Psychosomatics 1986; 27: 849–854
   Google Scholar
• Fesler FA: Valproate in combat-related posttraumatic stress disorder. J Clin Psychiatry 1991; 52:361–364
   PubMed Web of Science ®Google Scholar
• Clark RD, Canive JM, Calais LA, Qualls CR, Tuason VB:_Di-valproex in posttraumatic stress disorder: an open-label clini-cal trial. J Trauma Stress 1999; 12:395–401
   PubMed Web of Science ®Google Scholar
• Kitchner I, Greenstein R: Low dose lithium carbonate in the treatment of posttraumatic stress disorder: Brief communica-tion. Mil Med 1985; 150:378–381
   PubMedGoogle Scholar
• Berlant JL: Topiramate in posttraumatic stress disorder: Preliminary clinical observations. J Clin Psychiatry 2001; 62(17):60–63
   Google Scholar
• Berlant JL, van Kammen DP: Open-label topirimate as pri-mary or adjunctive therapy in chronic civilian posttraumatic stress disorder: A preliminary report. J Clin Psychiatry 2002; 63(1):15–20
   PubMed Web of Science ®Google Scholar
• Hertzberg MA, Butterfield MI, Feldman ME, Beckham JC, Sutherland SM, Connor KM, Davidson JR: A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry 1999; 45:1226–1229
   PubMed Web of Science ®Google Scholar
• Hamner MB, Bodrick PS, Labbate LA: Gabapentin in PTSD: A retrospective clinical series of adjunctive therapy. Ann Clin Psychiatry 2001:13:141–146
   PubMedGoogle Scholar
• Braun P, Green D, Dasberg H, Lerer B: Core symptoms of posttraumatic stress disorder unimproved by alprazolam treat-ment. J Clin Psychiatry 1990; 51:236–238
   PubMed Web of Science ®Google Scholar
• Gelpin E, Bonne O, Pen T, Brandes D, Shalev AY: Treament of recent trauma survivors with bensodiazepines: A prospective study. J Clin Psychiatry 1996; 57:390–394
   PubMed Web of Science ®Google Scholar
• Risse SC, VVhitters A, Burke J. Chen S, Scurfield RM, Raskind MA: Severe withdrawal symptoms after discontin-uation of alprazolam in eight patients with combat-induced post-traumatic stress disorder. J Clin Psychiatry 1990; 51:206–209
   Google Scholar
• Famularo R, Kinscherff R, Fenton T: Propranolol treatment for childhood post-traumatic stress disorder, acute type: A pi-lot study. Am J Dis Child 1988; 142:1244–1247
   PubMedGoogle Scholar
• Friedman MJ, Southwick SM: Towards pharmacotherapy for PTSD. In Friedman MJ, Charney DS, Deutch AY, eds. Nerobi-ological and Clinical Consequences of Stress: From Normal Adaptation to PTSD. Philadelphia, PA: Lippincott-Raven; 1995:465–481
   Google Scholar
• Kinzie JD, Leung P: Clonidine in Cambodian patients with posttraumatic stress disorder. J Nerv Ment Dis 1989; 177:546–550
   PubMed Web of Science ®Google Scholar
• Taylor F, Raskind MA: The alpha adrenergic antagonist pra-zosin improves sleep and nightmares in civilian trauma post-traumatic stress disorder. 3 Clin Psychopharmcol 2002; 22:82–85
   PubMed Web of Science ®Google Scholar
• Raskind MA, Dobie DJ, Kanter ED, Petrie EC, Thompson CE, Peskind ER: The alpha adrenergic antaonist prazosin amelio-rates combat trauma nightmares in veterans with posttrau-matic stress disorder: A report of four cases. J Clin Psychiatry 2000; 61(2):129–133
   Google Scholar
• Faustman WO, White PA: Diagnostic and psychopharmaco-logical treatment characteristics of 536 inpatients with post-traumatic stress disorder. I Nerv Ment Dis 1989; 177:154–159
   PubMed Web of Science ®Google Scholar
• Birklimer Li, DeVane CL, Muniz CE: Posttraumatic stress disorder: Characteristics and pharmacological response in the veteran population. Compreh Psychiatry 1985; 26(3):304–310
   Google Scholar
• Ciccone PE, Amzarek A, Weisbrot M, Greenstein RA, Olsen K, Zimmerman 3: Pharmacotherapy for PTSD. Am J Psychi-atry 1988; 145(10:1484–1485
   Google Scholar
• Sernyak MJ, Kosten TR, Fontana A, Rosenheck R: Neurolep - tic use in the treatment of posttraumatic stress disorder. Psy-chiatr Q 2001; 72(3):197–213
   PubMed Web of Science ®Google Scholar
• Bleich A. Siegel B, Garb R, Lerer B: Posttraumatic stress dis - . order following combat exposure: Clinical features and psy-chopharmacological treatment. Br J Psychiatry 1986; 149: 365––369
   Google Scholar
• Dillard ML, Bendfeldt F, Jernigan P: Use of thioridazine in posttraumatic stress disorder. South Med J 1993; 86(11):1276–1278
   Google Scholar
• Eidelman I, Seedat S, Stein DJ: Risperidone in the treatment of acute stress disorder in physically traumatized inpatients. Depress Anxiety 2000; 11:187–188
   PubMedGoogle Scholar
• Leyba CM: Risperidone in PTSD. Psychiatr Serv 1998; 49: 245––246
   Google Scholar
• Krashin D. Oates EW: Risperidone as an adjunct therapy for posttraumatic stress disorder. Mil Med 1999; 8:605–606
   Google Scholar
• Monnelly EP, Ciraulo DA: Risperidone effects on irritable ag-gression in posttraumatic stress disorder. J Clin Psychophar-macol 1999; 19:377–378
   PubMedGoogle Scholar
• Hamner MB, Ulmer HG, Faldowski RA, Frueh BC, Twomey TJ, Tyson C, Lorberbaum JP, Teneback CC, Huber MG, Arana GW: A randomized, controlled trial of risperidone for psy-chotic features in PTSD. Int J Neuropsychopharmacol 2000: 3:S141
   Google Scholar
• Petty F. Brannan S. Casada J. Davis LL, Gajewski V. Kramer GL, Stone RC, Teten AL, Worchel J. Young KA: Olanzap-Me treatment for posttraumatic stress disorder: An open-label study. Int. Clin Psychopharmacol 2001; 16:331–337
   Google Scholar
• Butterfield M, Becker ME, Connor KM, Sutherland S, Churchill LE, Davidson JRT: Olanzapine in the treatment of posttraumatic stress disorder. Int Clin Psychopharmacol 2001; 16:197–203
   PubMed Web of Science ®Google Scholar
• Stein MB, Kline NA, Matloff JL: Adjunctive olanzapine for SSRI-resistant combat-related PTSD: A double-blind, placebo-controlled study. Am J Psychiatry 2002; 159:1777–1779
   PubMed Web of Science ®Google Scholar
• Labatte L, Douglas S: Olanzapine for nightmares and sleep disturbance in posttraumatic stress disorder. Can J Psychiatry 2000; 45(7):667–668
   Google Scholar
• Prior TI: Treatment of posttraumatic stress disorder with olan-zapine. Can J Psychiatry 2001; 46:182
   Google Scholar
• Hamner MB: Clozapine treatment for a veteran with comorbid psychosis and PTSD. Am J Psych 1996; 153(6):841
   Web of Science ®Google Scholar
• Friedman MJ: What might the psychobiology of posttraumatic stress disorder teach us about future approaches to pharma-cotherapy? J Clin Psychiatry 2000; 61(Suppl 7):44–51
   PubMed Web of Science ®Google Scholar
• Southwick SM, Yehuda R, Morgan CA: Clinical studies of neu-rotransmitter alterations in posttraumatic stress disorder. In: Friedman MJ, Charney DS, Deutch AY, eds. Neurobiological and Clinical Consequences of Stress: From Normal Adapta-tion to PTSD. Philadelphia, PA: Lippincott-Raven; 1995:335–349
   Google Scholar
• DeBellis MD, Chrousos GP, Dorn LD, Burke L, Helmers K, Kling MA, Trickett PK, Putnam FW: Hypothalamic-pituitary-adrenal axis dysregulation in sexually abused girls. J Clin En-docrinol Metab 1994; 78:249–255
   PubMed Web of Science ®Google Scholar
• Davis LL, Suns A, Lambert MT, Heinberg C, Petty F: Post-traumatic stress disorder and serotonin: New directions for research and treatment. J Psychiatry Neurosci 1997; 22:318–326
   PubMed Web of Science ®Google Scholar
• Tollefson GD, Sanger TM, Lu Y, 'Thieme ME: Depressive signs and symptoms in schizophrenia: A prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 1998; 55:250–258
   PubMed Web of Science ®Google Scholar
• Tucker P, Trautman R: Understanding and treating PTSD: Past, present, and future. Bull Meninger Clin 2000; 64(3, Suppl A):37–51
   Google Scholar
• Shelton RC, Tollefson GD, Tohen M. Stahl S, Gannon KS, Jacobs TG, Buras WR, Bymaster FP, Zhang W, Spencer KA, Feldman PD, Meltzer HY: A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001; 158:131–134
   Google Scholar
• Weisler RH, Ahearn EP, Davidson JT, Wallace R: Adjunctive use of olanzapine in mood disorders: Five case reports. Ann Clin Psychiatry 1997; 9:259–262
   PubMedGoogle Scholar
• Tollefson GD, Sanger TM, Lu Y, Thieme ME: Depressive signs and symptoms in schizophrenia: A prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 1998; 55:250–258
   PubMed Web of Science ®Google Scholar
• Rothschild AJ, Bates KS, Boehringer KL, Syed A: Olanzap-ine response in psychotic depression. J Clin Psychiatry 1999; 60(2):116–118
   PubMedGoogle Scholar
• Soloff PH, George A, Nathan RS, Schulz PM, Ulrich RF, Pere JM: Progress in pharmacotherapy of borderline disor-ders. Arch Gen Psychiatry 1986; 43:691–697
   PubMed Web of Science ®Google Scholar
• Cowdry RW, Gardner DL: Pharmacotherapy of borderline personality disorder. Arch Gen Psychiatry 1988; 45:111–119
   PubMed Web of Science ®Google Scholar
• Barnett SD, Kramer ML, Casat CD, Connor KM, Davidson JR: Efficacy of olanzapine in social anxiety disorder: A pilot study. J Psychopharmacol 2002; 16(4):365–368
   PubMed Web of Science ®Google Scholar
• Charney DS, Deutch AY, Krystal JH, Southwick SM, Davis M: Psychobiological mechanisms of posttraumatic stress disorder. Arch Gen Psychiatry 1993; 50:295–305
   PubMed Web of Science ®Google Scholar
• Thierry AM, Tassin TP, Blanc G, Glowinski J: Selective acti-vation of the mesocortical dopamine system by stress. Nature 1976; 203:242–244
   Google Scholar
• Mantz J, 'Thierry AM, Glowinski J: Effect of noxious tail pinch on the discharge rate of mesocortical and mesolimbic dopamine neurons: Selective activation of the mesocortical system. Brain Res 1989; 476:377–381
   Google Scholar
• Yehuda R, Southwick S, Giller EL, Ma X, Mason .TW: Urinary catecholamine excretion and severity of PTSD symptoms in Vietnam combat veterans. J Nerv Ment Dis 1992; 180:321–325
   Google Scholar
• Hamner M. Diamond BI: Elevated plasma dopamine in post-traumatic stress disorder: A preliminary report. Biol Psychia-try 1993; 33:304–306
   PubMedGoogle Scholar
• Marx CE, VanDoren MJ, Duncan GE, Lieberman JA, Mor-row AL: Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents. Neuropsy-chopharmacology 2003; 28:1–13
   PubMed Web of Science ®Google Scholar
• Marx CE, Duncan GE, Gilmore JH, Lieberman JA, Morrow AL: Olanzapine increases allopregnanolone in the rat cerebral cortex. Biol Psychiatry 2000; 47:1000–1004
   Google Scholar
• Uzunova V, Sheline Y, Davis JM, Rasmusson A, Uzunov DP, Costa E, Guidotti A: Increase in the cerebrospinal fluid con-tent of neurosteroids in patients with unipolar major depres-sion who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci USA 1998; 95:3239–3244
   PubMed Web of Science ®Google Scholar
• Romeo E, Str A. Spalletta G, di Michele F, Hermann B, Hols-boer F, Pasini A. Rupprecht R: Effects of antidepressant treat-ment on neuroactive steroids in major depression. Am J Psy-chiatry 1998; 155:910–913
   Google Scholar
• Crawley JN, Glowa JR, Majewska MD, Paul SM: Anxiolytic activity of an endogenous adrenal steroid. Brain Res 1986; 398:382–385
   PubMed Web of Science ®Google Scholar
• Wieland S, Lan NC, Mirasedeghi S. Gee KW: Anxiolytic activ-ity of the progesterone metabolite 5alpha-pregnan-3alpha-ol-20-one. Brain Res 1991; 565:263–268
   Google Scholar